TY - JOUR
T1 - Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population
T2 - Three-year clinical outcomes
AU - Park, Ji Young
AU - Rha, Seung Woon
AU - Choi, Byoung Geol
AU - Choi, Jae Woong
AU - Ryu, Sung Kee
AU - Kim, Seunghwan
AU - Noh, Yung Kyun
AU - Choi, Se Yeon
AU - Akkala, Raghavender Goud
AU - Li, Hu
AU - Ali, Jabar
AU - Xu, Shaopeng
AU - Ngow, Harris Abdullah
AU - Lee, Jae Joong
AU - Lee, Gwang No
AU - Kim, Ji Bak
AU - Lee, Sunki
AU - Na, Jin Oh
AU - Choi, Cheol Ung
AU - Lim, Hong Euy
AU - Kim, Jin Won
AU - Kim, Eung Ju
AU - Park, Chang Gyu
AU - Seo, Hong Seog
AU - Oh, Dong Joo
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.
AB - Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.
KW - Atorvastatin
KW - New onset diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84933556998&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2015.03.047
DO - 10.1016/j.ijcard.2015.03.047
M3 - Article
C2 - 25756579
AN - SCOPUS:84933556998
SN - 0167-5273
VL - 184
SP - 502
EP - 506
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -